News

IMA Active’s new tablet press machine, Prexima, is designed to deliver higher productivity and efficiency.

West Pharmaceutical Services and HealthPrize Technologies are collaborating on self-reporting and bar coding capabilities for injectable drug-delivery systems.

The fully humanized monoclonal antibody is licensed to Bristol-Myers Squibb.

BASF is working together with top universities to develop a new supersonic spray-drying process for production of stable and soluble amorphous nanoparticles.

Piramal says pharmaceutical companies should strive to improve their processes, not just for original patented products but efforts should go beyond DMF and ANDA submissions.

Supersonic spray-drying process yields stable and soluble amorphous nanoparticles.

Appropriate cleaning procedures are crucial for any cGMP aseptic or sterile pharmaceutical manufacturing process, including vial filling; operators share best practices for cleaning.

EMD Millipore, the Life Science business of Merck KGaA, introduced expanded documentation and regulatory information for its Emprove portfolio of pharmaceutical raw materials, which include excipients, process chemicals, and APIs.

The agency cited Pan Drugs Limited with improper cleaning of facilities and equipment.

EDQM clarifies elemental impurities guidelines for veterinary and other products.

The White House nominates Robert Califf to head FDA, but will he be confirmed?

Nexvet Biopharma, a veterinary biologics developer, secured a dedicated, cGMP biologics manufacturing facility in Tullamore, Ireland, and plans to invest in disposable technology.

The Duran Group’s acquisition of Wheaton combine two brands of laboratory consumables.

Polydrug Laboratories is issued a US import alert, following similar bans in Canada and Europe.

FDA issues warning letter to Jaychem Industries, Auckland, New Zealand for violating CGMP regulations.

President Obama will nominate Rob Califf, current deputy commissioner for medical products and tobacco, as FDA commissioner.

GS1 standard tracks movement and status of goods, enabling better visibility, security and regulatory compliance.

Abenza acquired biopharmaceutical CDMO PacificGMP and expanded the company’s San Diego facility.

PharmSource forecasts slow growth in a new report on the outlook for the contract manufacturing industry.

According to AstraZeneca, the purchase of the biologics bulk plant will double the company's biologics manufacturing capacity in the US.

Source BioScience announced that it has acquired the next-generation sequencing services business from Oxford Gene Technology (OGT) in a move to expand its products and services portfolio.

MGB Biopharma, a biopharmaceutical company specializing in the development of novel anti-infectives to antibiotic resistance, has been named a winner in the 2015 Scottish Business Insider Deals & Dealmakers Awards.

SGS Life Science Services announced that its facility in Fairfield, NJ, has been upgraded to be Biosafety Level 2 (BSL-2) compliant, according to the Centers for Disease Control and Prevention (CDC) guidelines.

Under a global strategic partnership, Siemens will become GSK’s preferred supplier of manufacturing automation, focusing on process control, equipment control, and building management systems.

Lannett Company agreed to purchase Kremers Urban Pharmaceuticals, the US specialty generic-pharmaceuticals subsidiary of global biopharmaceuticals company UCB S.A., for $1.23 billion.

Mumbai-based Cipla agreed to acquire US companies InvaGen and Exelan, giving Cipla US tablet and capsule production capacity, a more diversified portfolio, and market access.

Aragen Bioscience has licensed ProteoNic Biotechnology’s 2G UNic recombinant protein production technology, which increases manufacturing efficiency and reduces cost of goods for recombinant biologicals.

FDA warns that compounded or repackaged drugs stored in certain syringes made by Becton-Dickinson may lose potency because of an interaction with the rubber stopper.

FDA publishes the final Q3D Elemental Impurities guidance.

This agreement is a follow-on to an established collaboration between LobSor and Recipharm for the development and the manufacturing of Lecigon batches for the recently completed clinical trial.